Generics BulletinThe latest meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use resulted in a raft of positive opinions for the off-patent industry. After eight denosumab nods in
Generics BulletinViatris continues to expect to submit a request for a US Food and Drug Administration re-inspection midyear for its stricken oral finished dose manufacturing facility in Indore, India. The warning let
Generics BulletinViatris will be able to launch generic versions of Heron Therapeutics’ Cinvanti (aprepitant) and Aponvie (aprepitant) injectable emulsion brands for nausea and vomiting around three years before paten
ScripViatris expects to file a fast-acting formulation of the established analgesic meloxicam (MR-107A-02) for US Food and Drug Administration approval during the second half of 2025, the company said duri